Last reviewed · How we verify
Second-line systemic treatment — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Second-line systemic treatment (Second-line systemic treatment) — Instituto de Investigación Hospital Universitario La Paz. Second-line systemic treatment refers to a category of therapeutic interventions administered after first-line therapy has failed or become unsuitable, rather than a single drug with a defined mechanism.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Second-line systemic treatment TARGET | Second-line systemic treatment | Instituto de Investigación Hospital Universitario La Paz | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Second-line systemic treatment CI watch — RSS
- Second-line systemic treatment CI watch — Atom
- Second-line systemic treatment CI watch — JSON
- Second-line systemic treatment alone — RSS
Cite this brief
Drug Landscape (2026). Second-line systemic treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/second-line-systemic-treatment. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab